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We thank Biondi-Zoccai and colleagues for their correspondence(1). They query a secondary 
finding in our study regarding the lack of difference between the two electronic cigarette 
(EC) arms(2). However, they also admit in their letter that the risks of nicotine without 
tobacco combustion are low. Whilst nicotine may exert pharmacologic effects, we tested 
the acute impact of switching away from tobacco cigarettes (TC) in the design of VESUVIUS. 
We state clearly that avoidance of tobacco toxicants may have produced the majority of the 
benefit seen as both EC arms demonstrated significant benefit over TC. Clearly, further 
investigation is required to understand the impact of nicotine on longer term vascular 
function. It should also be noted that larger randomized clinical trials on nicotine 
replacement therapy have not shown these to be associated with an increased CV risk (3). 
In relation to the lack of difference seen in other biomarkers, they quote their own work in a 
smaller study which is not significantly different from our primary finding i.e. switching to EC 
has less unfavorable impact than TC in the acute phase. Furthermore, the biomarkers we 
examined were qualitatively different from those analysed by their study. Changes in pulse 
wave velocity indicate change in structure. Changes in Flow Mediated Dilatation that was 
observed in our trial indicate change in function which temporally precedes structural 
change. Therefore, longer term follow-up studies could yield further positive benefits from 
switching. 
They question the replacement of dropouts in order to achieve adequate power in each 
group. Firstly, this was a mechanistic exploratory study and the pre-specified primary 
analysis was per protocol. Secondly, there is no question of bias as all patients were 
randomized into either EC arm until a minimum of 36 participants were achieved in each 
group for adequate power. Furthermore, an intention to treat analysis would not answer 
their question about nicotine as by definition, those who dropped out did not attend for 
their post-switch vascular assessment. Therefore no data would be available on the efficacy 
of EC with versus without nicotine in drop-outs. 
Finally, they note that the choice of EC may not be comparable to other devices. This is 
discussed in the Limitations section. We used a common EC device closest to the most 
popular EC strength in surveys(4) which would be broadly representative of public use in the 
UK but we agree that further comparisons are worthwhile. 
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